Taisho Pharmaceutical Holdings Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TAIPY research report →
About the company
Taisho Pharmaceutical Holdings Co. , Ltd. is a global healthcare entity engaged in the comprehensive process of researching, developing, manufacturing, marketing, distributing, and selling both over-the-counter (OTC) and prescription pharmaceutical products.
- CEO
- Akira Uehara
- IPO
- 2021
- Employees
- 8,784
- HQ
- Tokyo, JP
Price Chart
- Market Cap
- $18.13B
- P/E
- 37.03
- P/B
- 0.89
- Div Yield
- 0.00%
- Gross Margin
- 59.01%
- Op Margin
- 7.64%
- Net Margin
- 6.30%
- ROE
- 2.48%
- Revenue
- $301.38B · 12.37%
- Net Income
- $19.00B · 44.77%
- EPS
- $231.73 · 43.82%
- Op Income
- $23.02B
- FCF YoY
- -166.64%
- 52W High
- $15.52
- 52W Low
- $8.88
- 50D MA
- $12.20
- 200D MA
- $12.93
- Beta
- 0.44
- Avg Volume
- 202
Get TickerSpark's AI analysis on TAIPY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our TAIPY coverage
Recent articles, reports, and earnings notes.
No research on TAIPY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TAIPY report →